- Education, Training & Outreach
- Patients & Caregivers
- For Investigators
- Dementia in the News
- Media Room
A Randomized, 18-Week, Placebo-Controlled, Double-Blind, Parallel-Group Study of the Safety and Efficacy of PF-05212377 (SAM-760) in Subjects with Mild to Moderate AD with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil
The purpose of this clinical trial is to evaluate the safety of PF-05212377 (SAM-760) and the effect of PF-05212377 (SAM-760) on cognition and some behavioral symptoms associated with Alzheimer's disease.
We are looking for participants who:
-- have a diagnosis of Alzheimer's disease
-- are age 60 or older
-- have a reliable caregiver or family member who is able to accompany them to study visits
-- are in stable medical condition
-- are on stable doses of Aricept (donepezil)
-- are not on any other medications for Alzheimer's disease (antidepressants are allowed)
More information is attached.
|RecruitmentDocument (5).pdf||45.14 KB|